<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00765765</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000615000</org_study_id>
    <secondary_id>P30CA072720</secondary_id>
    <secondary_id>CINJ-040804</secondary_id>
    <secondary_id>0220080205</secondary_id>
    <nct_id>NCT00765765</nct_id>
  </id_info>
  <brief_title>Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast Cancer</brief_title>
  <official_title>Phase I/II Study of Ixabepilone in Combination With the Autophagy Inhibitor Hydroxychloroquine for the Treatment of Patients With Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Medicine and Dentistry of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop&#xD;
      the growth of tumor cells, either by killing the cells or by stopping them from dividing.&#xD;
      Hydroxychloroquine may help ixabepilone work better by making tumor cells more sensitive to&#xD;
      the drug.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of ixabepilone&#xD;
      given together with hydroxychloroquine and to see how well they work in treating patients&#xD;
      with metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  The primary objective of this study is to assess the antitumor activity, measured by&#xD;
           tumor response rate, in patients who receive this regimen as a third-line treatment.&#xD;
           (Phase II)&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To measure the duration of response for responding patients.&#xD;
&#xD;
        -  To measure the time to progressive disease.&#xD;
&#xD;
        -  To measure survival time.&#xD;
&#xD;
        -  To characterize the quantitative and qualitative toxicities of this regimen in these&#xD;
           patients.&#xD;
&#xD;
        -  To develop pharmacodynamic markers for autophagy detection in patient specimens.&#xD;
&#xD;
        -  To characterize the effects of hydroxychloroquine on autophagy in patients in vivo.&#xD;
&#xD;
        -  To investigate whether the estrogen receptor, progesterone receptor, and/or HER2 status&#xD;
           of breast tumors correlates with treatment response.&#xD;
&#xD;
      OUTLINE: This is a multicenter, phase I dose-escalation study of ixabepilone followed by a&#xD;
      phase II study.&#xD;
&#xD;
      During the first course, patients receive ixabepilone IV over 3 hours on day 1 and oral&#xD;
      hydroxychloroquine twice daily on days 3-21. On all subsequent courses, patients receive&#xD;
      ixabepilone IV over 3 hours on day 1 and oral hydroxychloroquine twice daily on days 1-21.&#xD;
      Treatment repeats every 21 days in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      After completion of study therapy, patients are followed every 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual&#xD;
  </why_stopped>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor Response Rate</measure>
    <time_frame>3 years</time_frame>
    <description>Overall Complete Response and Partial Response will be considered tumor response. Ixabepilone as a single agent (40 mg/m2 as an intravenous infusion every 3 weeks) was evaluated in a previous (Phase II) study in women with metastatic breast cancer and that the objective tumor response rate was 11.5%. In another(Phase III) study, Ixabepilone in combination with capecitabine resulted in an objective tumor response rate of 35%, compared to that of capecitabine alone (14%). Therefore, in the Phase II portion of the ixabepilone plus hydroxychloroquine combination treatment study, a tumor response rate of less than 15% will be deemed uninteresting. The target tumor response rate will be 35%. Due to uncertainty about the true response rate of ixabepilone plus hydroxychloroquine combination on this patient poupation, we also will consider a response rate of 30% to be encouraging.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progressive Disease</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival Time</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Markers for Autophagy Detection</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of Hydroxychloroquine on Autophagy</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of Estrogen Receptor, Progesterone Receptor and/or HER2 Status With Treatment Response</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Ixabepilone and hydroxychloroquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydroxychloroquine</intervention_name>
    <description>Dose escalation from 200 mg po qd to 200 mg po bid.</description>
    <arm_group_label>Ixabepilone and hydroxychloroquine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ixabepilone</intervention_name>
    <description>Starting dose of 40 mg/m2 and can dose reduce to 32 mg/m2.</description>
    <arm_group_label>Ixabepilone and hydroxychloroquine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed breast cancer&#xD;
&#xD;
               -  Histologic or cytologic elements can be established on metastatic tumor aspirate&#xD;
                  or biopsy&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
               -  Measurable disease according to RECIST criteria&#xD;
&#xD;
          -  Must have received 2 prior chemotherapy regimens for metastatic breast cancer&#xD;
&#xD;
          -  Anthracycline-resistant (or treated with minimum cumulative doxorubicin dose of 240&#xD;
             mg/m^2 or epirubicin dose of 360 mg/m^2) and taxane-resistant disease&#xD;
&#xD;
               -  Anthracycline resistance is defined as progression while on therapy or within 6&#xD;
                  months in the adjuvant/neoadjuvant setting or 3 months in the metastatic setting&#xD;
&#xD;
               -  Taxane resistance is defined as progression while on therapy or within 12 months&#xD;
                  in the adjuvant/neoadjuvant setting or 4 months in the metastatic setting&#xD;
&#xD;
          -  Hormone receptor status known&#xD;
&#xD;
          -  No known CNS metastases or previously treated and now stable CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Menopausal status not specified&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  ANC ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  Total bilirubin ≤ upper limit of normal (ULN)&#xD;
&#xD;
               -  If patient has Gilbert's disease, then patient must have isolated&#xD;
                  hyperbilirubinemia (e.g., no other liver function test abnormality), with maximum&#xD;
                  bilirubin ≤ 2 times ULN&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times ULN, independently of liver metastases&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN OR calculated creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other active malignancy&#xD;
&#xD;
               -  History of basal cell or squamous cell carcinoma of the skin or carcinoma in situ&#xD;
                  of the cervix within the past 3 years allowed provided patient has been treated&#xD;
                  with curative intent&#xD;
&#xD;
               -  History of prior malignancy allowed provided patient has been treated with&#xD;
                  curative intent and has been disease free &gt; 3 years&#xD;
&#xD;
          -  None of the following conditions within the past 6 months:&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
               -  Stroke&#xD;
&#xD;
               -  Symptomatic peripheral vascular disease&#xD;
&#xD;
          -  No unstable angina or NYHA class II-IV congestive heart failure&#xD;
&#xD;
          -  No history of psoriasis or porphyria&#xD;
&#xD;
          -  No history of hypersensitivity to 4-aminoquinoline compound&#xD;
&#xD;
          -  No retinal or visual field changes from prior 4-aminoquinoline-compound use&#xD;
&#xD;
          -  No history of G6PD deficiency&#xD;
&#xD;
          -  No GI pathology that would interfere with drug bioavailability&#xD;
&#xD;
          -  No motor or sensory neuropathy ≥ grade 2 (NCI CTCAE) at study entry&#xD;
&#xD;
          -  No serious uncontrolled medical disorder or active infection at study entry&#xD;
&#xD;
          -  No rheumatoid arthritis or systemic lupus erythematosus requiring active treatment&#xD;
&#xD;
          -  No history of HIV&#xD;
&#xD;
          -  No history of any condition (social or medical) that, in the opinion of the&#xD;
             investigator, might interfere with the patient's ability to comply with the protocol&#xD;
             or pose additional or unacceptable risk to the patient&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior radiation to tumor sites allowed provided:&#xD;
&#xD;
               -  Radiation was completed ≥ 3 weeks prior to study treatment&#xD;
&#xD;
               -  All radiation-related toxicities have resolved to ≤ grade 1&#xD;
&#xD;
          -  No more than 3 prior chemotherapy regimens in the metastatic setting&#xD;
&#xD;
          -  No prior ixabepilone or another epothilone&#xD;
&#xD;
          -  No concurrent highly active antiretroviral therapy&#xD;
&#xD;
          -  No other concurrent hydroxychloroquine for treatment or prophylaxis of malaria&#xD;
&#xD;
          -  No other concurrent anticancer investigational or commercial agents or therapies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vassil Karantza-Wadsworth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers Cancer Institute of New Jersey</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey at Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>New Jersey</state>
        <zip>08690</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.gov/ct2/show/NCT00765765</url>
    <description>Clinical trial summary from the National Cancer Institute's PDQ® database</description>
  </link>
  <verification_date>November 2013</verification_date>
  <study_first_submitted>October 2, 2008</study_first_submitted>
  <study_first_submitted_qc>October 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2008</study_first_posted>
  <results_first_submitted>November 6, 2013</results_first_submitted>
  <results_first_submitted_qc>November 6, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 25, 2013</results_first_posted>
  <last_update_submitted>November 6, 2013</last_update_submitted>
  <last_update_submitted_qc>November 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>male breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Six subjects were recruited from The Cancer Institute of New Jersey (a comprehensive cancer center) and one of its affiliate community hospitals in New Jersey, from April 2009 through June 2010.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ixabepilone and Hydroxychloroquine</title>
          <description>ixabepilone : Starting dose of 40 mg/m2 and can dose reduce to 32 mg/m2.&#xD;
hydroxychloroquine : Dose escalation from 200 mg po qd to 200 mg po bid.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ixabepilone and Hydroxychloroquine</title>
          <description>ixabepilone : Starting dose of 40 mg/m2 and can dose reduce to 32 mg/m2.&#xD;
hydroxychloroquine : Dose escalation from 200 mg po qd to 200 mg po bid.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.7" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <time_frame>5 years</time_frame>
        <population>The study was closed early due to slow accrual. Insufficient data were collected to analyze this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone and Hydroxychloroquine</title>
            <description>ixabepilone : Starting dose of 40 mg/m2 and can dose reduce to 32 mg/m2.&#xD;
hydroxychloroquine : Dose escalation from 200 mg po qd to 200 mg po bid.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <population>The study was closed early due to slow accrual. Insufficient data were collected to analyze this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progressive Disease</title>
        <time_frame>5 years</time_frame>
        <population>The study was closed early due to slow accrual. Insufficient data were collected to analyze this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone and Hydroxychloroquine</title>
            <description>ixabepilone : Starting dose of 40 mg/m2 and can dose reduce to 32 mg/m2.&#xD;
hydroxychloroquine : Dose escalation from 200 mg po qd to 200 mg po bid.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progressive Disease</title>
          <population>The study was closed early due to slow accrual. Insufficient data were collected to analyze this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival Time</title>
        <time_frame>5 years</time_frame>
        <population>The study was closed early due to slow accrual. Insufficient data were collected to analyze this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone and Hydroxychloroquine</title>
            <description>ixabepilone : Starting dose of 40 mg/m2 and can dose reduce to 32 mg/m2.&#xD;
hydroxychloroquine : Dose escalation from 200 mg po qd to 200 mg po bid.</description>
          </group>
        </group_list>
        <measure>
          <title>Survival Time</title>
          <population>The study was closed early due to slow accrual. Insufficient data were collected to analyze this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamic Markers for Autophagy Detection</title>
        <time_frame>2 years</time_frame>
        <population>The study was closed early due to slow accrual. Insufficient data were collected to analyze this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone and Hydroxychloroquine</title>
            <description>ixabepilone : Starting dose of 40 mg/m2 and can dose reduce to 32 mg/m2.&#xD;
hydroxychloroquine : Dose escalation from 200 mg po qd to 200 mg po bid.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamic Markers for Autophagy Detection</title>
          <population>The study was closed early due to slow accrual. Insufficient data were collected to analyze this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effects of Hydroxychloroquine on Autophagy</title>
        <time_frame>2 years</time_frame>
        <population>The study was closed early due to slow accrual. Insufficient data were collected to analyze this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone and Hydroxychloroquine</title>
            <description>ixabepilone : Starting dose of 40 mg/m2 and can dose reduce to 32 mg/m2.&#xD;
hydroxychloroquine : Dose escalation from 200 mg po qd to 200 mg po bid.</description>
          </group>
        </group_list>
        <measure>
          <title>Effects of Hydroxychloroquine on Autophagy</title>
          <population>The study was closed early due to slow accrual. Insufficient data were collected to analyze this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation of Estrogen Receptor, Progesterone Receptor and/or HER2 Status With Treatment Response</title>
        <time_frame>5 years</time_frame>
        <population>The study was closed early due to slow accrual. Insufficient data were collected to analyze this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone and Hydroxychloroquine</title>
            <description>ixabepilone : Starting dose of 40 mg/m2 and can dose reduce to 32 mg/m2.&#xD;
hydroxychloroquine : Dose escalation from 200 mg po qd to 200 mg po bid.</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of Estrogen Receptor, Progesterone Receptor and/or HER2 Status With Treatment Response</title>
          <population>The study was closed early due to slow accrual. Insufficient data were collected to analyze this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tumor Response Rate</title>
        <description>Overall Complete Response and Partial Response will be considered tumor response. Ixabepilone as a single agent (40 mg/m2 as an intravenous infusion every 3 weeks) was evaluated in a previous (Phase II) study in women with metastatic breast cancer and that the objective tumor response rate was 11.5%. In another(Phase III) study, Ixabepilone in combination with capecitabine resulted in an objective tumor response rate of 35%, compared to that of capecitabine alone (14%). Therefore, in the Phase II portion of the ixabepilone plus hydroxychloroquine combination treatment study, a tumor response rate of less than 15% will be deemed uninteresting. The target tumor response rate will be 35%. Due to uncertainty about the true response rate of ixabepilone plus hydroxychloroquine combination on this patient poupation, we also will consider a response rate of 30% to be encouraging.</description>
        <time_frame>3 years</time_frame>
        <population>The study was closed early due to slow accrual. Insufficient data were collected to evaluate this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone and Hydroxychloroquine</title>
            <description>ixabepilone : Starting dose of 40 mg/m2 and can dose reduce to 32 mg/m2.&#xD;
hydroxychloroquine : Dose escalation from 200 mg po qd to 200 mg po bid.</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Response Rate</title>
          <description>Overall Complete Response and Partial Response will be considered tumor response. Ixabepilone as a single agent (40 mg/m2 as an intravenous infusion every 3 weeks) was evaluated in a previous (Phase II) study in women with metastatic breast cancer and that the objective tumor response rate was 11.5%. In another(Phase III) study, Ixabepilone in combination with capecitabine resulted in an objective tumor response rate of 35%, compared to that of capecitabine alone (14%). Therefore, in the Phase II portion of the ixabepilone plus hydroxychloroquine combination treatment study, a tumor response rate of less than 15% will be deemed uninteresting. The target tumor response rate will be 35%. Due to uncertainty about the true response rate of ixabepilone plus hydroxychloroquine combination on this patient poupation, we also will consider a response rate of 30% to be encouraging.</description>
          <population>The study was closed early due to slow accrual. Insufficient data were collected to evaluate this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year, 8 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ixabepilone and Hydroxychloroquine</title>
          <description>ixabepilone : Starting dose of 40 mg/m2 and can dose reduce to 32 mg/m2.&#xD;
hydroxychloroquine : Dose escalation from 200 mg po qd to 200 mg po bid.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericardial effusion (non-malignant)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="15" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood/Bone Marrow - Other (Specify, __)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac General - Other (Specify, __)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision-flashing lights/floaters</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - Abdomen NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain - Back</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain - Bone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain - Chest wall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain - Joint</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain - Muscle</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain - Other (Specify, __)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood alteration - Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hair loss/alopecia (scalp or body)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, pulmonary/upper respiratory - Nose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Vassiliki Karantza</name_or_title>
      <organization>Cancer Institute of New Jersey</organization>
      <phone>732-235-8675</phone>
      <email>karantva@cinj.rutgers.edu; rizzoji@cinj.rutgers.edu; zelinsta@cinj.rutgers.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

